368 related articles for article (PubMed ID: 26289069)
1. Absolute Effect of Prostate Cancer Screening: Balance of Benefits and Harms by Center within the European Randomized Study of Prostate Cancer Screening.
Auvinen A; Moss SM; Tammela TL; Taari K; Roobol MJ; Schröder FH; Bangma CH; Carlsson S; Aus G; Zappa M; Puliti D; Denis LJ; Nelen V; Kwiatkowski M; Randazzo M; Paez A; Lujan M; Hugosson J
Clin Cancer Res; 2016 Jan; 22(1):243-9. PubMed ID: 26289069
[TBL] [Abstract][Full Text] [Related]
2. Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
Schröder FH
Can J Urol; 2005 Feb; 12 Suppl 1():2-6; discussion 92-3. PubMed ID: 15780157
[TBL] [Abstract][Full Text] [Related]
3. Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial.
Arnsrud Godtman R; Holmberg E; Lilja H; Stranne J; Hugosson J
Eur Urol; 2015 Sep; 68(3):354-60. PubMed ID: 25556937
[TBL] [Abstract][Full Text] [Related]
4. Prostate cancer mortality in the Finnish randomized screening trial.
Kilpeläinen TP; Tammela TL; Malila N; Hakama M; Santti H; Määttänen L; Stenman UH; Kujala P; Auvinen A
J Natl Cancer Inst; 2013 May; 105(10):719-25. PubMed ID: 23479454
[TBL] [Abstract][Full Text] [Related]
5. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer.
Draisma G; Boer R; Otto SJ; van der Cruijsen IW; Damhuis RA; Schröder FH; de Koning HJ
J Natl Cancer Inst; 2003 Jun; 95(12):868-78. PubMed ID: 12813170
[TBL] [Abstract][Full Text] [Related]
6. Impacts of a population-based prostate cancer screening programme on excess total mortality rates in men with prostate cancer: a randomized controlled trial.
van Leeuwen PJ; Kranse R; Hakulinen T; Hugosson J; Tammela TL; Ciatto S; Roobol MJ; Zappa M; de Koning HJ; Bangma CH; Moss SM; Auvinen A; Schröder FH
J Med Screen; 2013 Mar; 20(1):33-38. PubMed ID: 28075228
[TBL] [Abstract][Full Text] [Related]
7. The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials.
de Koning HJ; Gulati R; Moss SM; Hugosson J; Pinsky PF; Berg CD; Auvinen A; Andriole GL; Roobol MJ; Crawford ED; Nelen V; Kwiatkowski M; Zappa M; Luján M; Villers A; de Carvalho TM; Feuer EJ; Tsodikov A; Mariotto AB; Heijnsdijk EAM; Etzioni R
Cancer; 2018 Mar; 124(6):1197-1206. PubMed ID: 29211316
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data.
Heijnsdijk EA; de Carvalho TM; Auvinen A; Zappa M; Nelen V; Kwiatkowski M; Villers A; Páez A; Moss SM; Tammela TL; Recker F; Denis L; Carlsson SV; Wever EM; Bangma CH; Schröder FH; Roobol MJ; Hugosson J; de Koning HJ
J Natl Cancer Inst; 2015 Jan; 107(1):366. PubMed ID: 25505238
[TBL] [Abstract][Full Text] [Related]
9. Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial.
de Koning HJ; Auvinen A; Berenguer Sanchez A; Calais da Silva F; Ciatto S; Denis L; Gohagan JK; Hakama M; Hugosson J; Kranse R; Nelen V; Prorok PC; Schröder FH; ;
Int J Cancer; 2002 Jan; 97(2):237-44. PubMed ID: 11774270
[TBL] [Abstract][Full Text] [Related]
10. Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence.
Hayes JH; Barry MJ
JAMA; 2014 Mar; 311(11):1143-9. PubMed ID: 24643604
[TBL] [Abstract][Full Text] [Related]
11. Number of Screening Rounds and Postscreening Prostate Cancer Incidence: Results from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer Study.
Pakarainen T; Raitanen J; Talala K; Taari K; Kujala P; Tammela TL; Auvinen A
Eur Urol; 2016 Sep; 70(3):499-505. PubMed ID: 27210461
[TBL] [Abstract][Full Text] [Related]
12. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context.
Draisma G; Etzioni R; Tsodikov A; Mariotto A; Wever E; Gulati R; Feuer E; de Koning H
J Natl Cancer Inst; 2009 Mar; 101(6):374-83. PubMed ID: 19276453
[TBL] [Abstract][Full Text] [Related]
13. Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC).
Schröder FH; Hugosson J; Carlsson S; Tammela T; Määttänen L; Auvinen A; Kwiatkowski M; Recker F; Roobol MJ
Eur Urol; 2012 Nov; 62(5):745-52. PubMed ID: 22704366
[TBL] [Abstract][Full Text] [Related]
14. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.
Schröder FH; Hugosson J; Roobol MJ; Tammela TL; Zappa M; Nelen V; Kwiatkowski M; Lujan M; Määttänen L; Lilja H; Denis LJ; Recker F; Paez A; Bangma CH; Carlsson S; Puliti D; Villers A; Rebillard X; Hakama M; Stenman UH; Kujala P; Taari K; Aus G; Huber A; van der Kwast TH; van Schaik RH; de Koning HJ; Moss SM; Auvinen A;
Lancet; 2014 Dec; 384(9959):2027-35. PubMed ID: 25108889
[TBL] [Abstract][Full Text] [Related]
15. A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer.
Hugosson J; Roobol MJ; Månsson M; Tammela TLJ; Zappa M; Nelen V; Kwiatkowski M; Lujan M; Carlsson SV; Talala KM; Lilja H; Denis LJ; Recker F; Paez A; Puliti D; Villers A; Rebillard X; Kilpeläinen TP; Stenman UH; Godtman RA; Stinesen Kollberg K; Moss SM; Kujala P; Taari K; Huber A; van der Kwast T; Heijnsdijk EA; Bangma C; De Koning HJ; Schröder FH; Auvinen A;
Eur Urol; 2019 Jul; 76(1):43-51. PubMed ID: 30824296
[TBL] [Abstract][Full Text] [Related]
16. Eighteen-year follow-up of the Göteborg Randomized Population-based Prostate Cancer Screening Trial: effect of sociodemographic variables on participation, prostate cancer incidence and mortality.
Hugosson J; Godtman RA; Carlsson SV; Aus G; Grenabo Bergdahl A; Lodding P; Pihl CG; Stranne J; Holmberg E; Lilja H
Scand J Urol; 2018 Feb; 52(1):27-37. PubMed ID: 29254399
[TBL] [Abstract][Full Text] [Related]
17. Could Differences in Treatment Between Trial Arms Explain the Reduction in Prostate Cancer Mortality in the European Randomized Study of Screening for Prostate Cancer?
Carlsson SV; Månsson M; Moss S; Kwiatkowski M; Recker F; Tammela TLJ; Bangma C; Roobol MJ; Auvinen A; Hugosson J
Eur Urol; 2019 Jun; 75(6):1015-1022. PubMed ID: 30928162
[TBL] [Abstract][Full Text] [Related]
18. Prostate-specific antigen screening in the United States vs in the European Randomized Study of Screening for Prostate Cancer-Rotterdam.
Wever EM; Draisma G; Heijnsdijk EA; Roobol MJ; Boer R; Otto SJ; de Koning HJ
J Natl Cancer Inst; 2010 Mar; 102(5):352-5. PubMed ID: 20142584
[TBL] [Abstract][Full Text] [Related]
19. A Detailed Evaluation of the Effect of Prostate-specific Antigen-based Screening on Morbidity and Mortality of Prostate Cancer: 21-year Follow-up Results of the Rotterdam Section of the European Randomised Study of Screening for Prostate Cancer.
de Vos II; Meertens A; Hogenhout R; Remmers S; Roobol MJ;
Eur Urol; 2023 Oct; 84(4):426-434. PubMed ID: 37029074
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]